Activity of aminocandin (IP960; HMR3270) compared with amphotericin B, itraconazole, caspofungin and micafungin in neutropenic murine models of disseminated infection caused by itraconazole-susceptible and -resistant strains of Aspergillus fumigatus.

No abstract is available for this paper.

• Publication year

  2010

• Venue

  International Journal of Antimicrobial Agents

• Publication date

  2010-02-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/j.ijantimicag.2009.09.029PMID 20015618
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Trends in the postmortem epidemiology of invasive fungal infections at a university hospital.

  2010cited by this paper
• Pharmacokinetics and Pharmacodynamics of a Novel Triazole, Isavuconazole: Mathematical Modeling, Importance of Tissue Concentrations, and Impact of Immune Status on Antifungal Effect

  2009cited by this paper
• Subcommittee on Antifungal Susceptibility Testing of the ESCMID European Committee for Antimicrobial Susceptibility Testing. EUCAST Technical Note on the method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for conidia-forming moulds.

  2009cited by this paper
• EUCAST Technical Note on the method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for conidia-forming moulds.

  2008cited by this paper
• Factors associated with overall and attributable mortality in invasive aspergillosis.

  2008cited by this paper
• Posaconazole in the management of refractory invasive fungal infections

  2008cited by this paper
• Caspofungin modulates inflammatory responses to Aspergillus fumigatus through stage-specific effects on fungal beta-glucan exposure.

  2007cited by this paper
• Multicentre determination of quality control strains and quality control ranges for antifungal susceptibility testing of yeasts and filamentous fungi using the methods of the Antifungal Susceptibility Testing Subcommittee of the European Committee on Antimicrobial Susceptibility Testing (AFST-EUCAST

  2007cited by this paper
• Academic Editor: Chris Kibbler, Royal Free Hospital London, United Kingdom

  2007cited by this paper
• Invasive Aspergillosis in patients with acute leukemia: update on morbidity and mortality--SEIFEM-C Report.

  2007cited by this paper
• Multicenter, noncomparative study of caspofungin in combination with other antifungals as salvage therapy in adults with invasive aspergillosis

  2006cited by this paper
• Micafungin (FK463), alone or in combination with other systemic antifungal agents, for the treatment of acute invasive aspergillosis

  2006cited by this paper
• Multi-azole resistance in Aspergillus fumigatus.

  2006cited by this paper
• Activity of aminocandin (IP960) compared with amphotericin B and fluconazole in a neutropenic murine model of disseminated infection caused by a fluconazole-resistant strain of Candida tropicalis.

  2005cited by this paper
• Effect of hypoxic conditions on in vitro susceptibility testing of amphotericin B, itraconazole and micafungin against Aspergillus and Candida.

  2004cited by this paper
• Development and Validation of a Quantitative Real-Time PCR Assay Using Fluorescence Resonance Energy Transfer Technology for Detection of Aspergillus fumigatus in Experimental Invasive Pulmonary Aspergillosis

  2003cited by this paper
• In Vivo Pharmacodynamics of HMR 3270, a Glucan Synthase Inhibitor, in a Murine Candidiasis Model

  2003cited by this paper
• Activity of micafungin (FK463) against an itraconazole-resistant strain of Aspergillus fumigatus and a strain of Aspergillus terreus demonstrating in vivo resistance to amphotericin B.

  2003cited by this paper
• Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis.

  2002cited by this paper
• Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis.

  2002cited by this paper
• The Antifungal Echinocandin Caspofungin Acetate Kills Growing Cells of Aspergillus fumigatus In Vitro

  2002cited by this paper
• Trends in mortality due to invasive mycotic diseases in the United States, 1980-1997.

  2001cited by this paper
• Quantitative PCR Assay To MeasureAspergillus fumigatus Burden in a Murine Model of Disseminated Aspergillosis: Demonstration of Efficacy of Caspofungin Acetate

  2001cited by this paper
• Effect of grapefruit juice on serum voriconazole concentrations in the mouse.

  2000cited by this paper
• Lack of correlation of in vitro amphotericin B susceptibility testing with outcome in a murine model of Aspergillus infection.

  2000cited by this paper
• In Vitro Activities of a New Lipopeptide Antifungal Agent, FK463, against a Variety of Clinically Important Fungi

  2000cited by this paper
• Efficacy of FK463, a New Lipopeptide Antifungal Agent, in Mouse Models of Disseminated Candidiasis and Aspergillosis

  2000cited by this paper
• Amphotericin B resistance of Aspergillus terreus in a murine model of disseminated aspergillosis.

  2000cited by this paper
• Efficacy of LY303366 against Amphotericin B-Susceptible and -Resistant Aspergillus fumigatus in a Murine Model of Invasive Aspergillosis

  1998cited by this paper
• In vitro preclinical evaluation studies with the echinocandin antifungal MK-0991 (L-743,872)

  1997cited by this paper
• Correlation between in-vitro susceptibility testing to itraconazole and in-vivo outcome of Aspergillus fumigatus infection.

  1997cited by this paper
• Efficacy of SCH-56592 in a temporarily neutropenic murine model of invasive aspergillosis with an itraconazole-susceptible and an itraconazole-resistant isolate of Aspergillus fumigatus

  1997cited by this paper
• Evaluation of the echinocandin antifungal MK-0991 (L-743,872): efficacies in mouse models of disseminated aspergillosis, candidiasis, and cryptococcosis

  1997cited by this paper
• Trends in the postmortem epidemiology of invasive fungal infections at a university hospital.

  1996cited by this paper
• Therapeutic outcome in invasive aspergillosis.

  1996cited by this paper
• Treatment of invasive aspergillosis with itraconazole.

  1989cited by this paper

• Transferosomes As A Promising Platform for Targeted Antifungal Drug Delivery

  2025cites this paper
• Succinylation modification provides new insights for the treatment of immunocompromised individuals with drug-resistant Aspergillus fumigatus infection

  2023cites this paper
• Pathogenicity and virulence of Aspergillus fumigatus

  2023cites this paper
• New holistic approach for the management of biofilm‐associated infections by myco‐metabolites

  2022cites this paper
• Fungi a Potential Source of Bioactive Metabolites an Indian Prospective

  2021cites this paper
• Comparative Genome Sequence Analyses of Geographic Samples of Aspergillus fumigatus—Relevance for Amphotericin B Resistance

  2020cites this paper
• The novel fungal CYP51 inhibitor VT-1598 displays classic dose-dependent antifungal activity in murine models of invasive aspergillosis.

  2020cites this paper
• The fungal cell wall as a target for the development of new antifungal therapies.

  2019cites this paper
• Antifungals discovery: an insight into new strategies to combat antifungal resistance

  2018cites this paper
• The antifungal pipeline: a reality check

  2017cites this paper
• A Penicillium chrysogenum által termelt antifungális fehérje (PAF) vizsgálata állatmodellben

  2017cites this paper
• Rodent Models of Invasive Aspergillosis due to Aspergillus fumigatus: Still a Long Path toward Standardization

  2017cites this paper
• Fungal Metabolites for the Control of Biofilm Infections

  2016cites this paper
• Antifungal Drugs: The Current Armamentarium and Development of New Agents

  2016cites this paper
• Newer patents in antimycotic therapy.

  2016cites this paper
• Role of vitamin D in diabetes mellitus and chronic kidney disease.

  2016cites this paper
• Application of a low molecular weight antifungal protein from Penicillium chrysogenum (PAF) to treat pulmonary aspergillosis in mice

  2016cites this paper
• Isolate-Dependent Growth, Virulence, and Cell Wall Composition in the Human Pathogen Aspergillus fumigatus

  2014cites this paper
• Treatment Options in Invasive Aspergillosis

  2014cites this paper
• Pharmacokinetics and Pharmacodynamics of Antifungals in Children: Clinical Implications

  2014cites this paper
• Newer antifungal agents

  2013cites this paper
• RECENT DEVELOPMENTS IN ANTIFUNGAL AGENTS Review Article

  2012cites this paper
• Total synthesis and structure-activity relationships of new echinocandin-like antifungal cyclolipohexapeptides.

  2012cites this paper
• New therapeutic approaches by using microorganism-derived compounds.

  2012cites this paper
• Invasive fungal diseases in children with hematological malignancies and stem cell transplant recipients

  2012cites this paper
• Insights in Antifungal Drug Discovery

  2012cites this paper
• Total synthesis and structure–activity relationships of caspofungin-like macrocyclic antifungal lipopeptides

  2012cites this paper
• Pharmacokinetics and pharmacodynamics of posaconazole for invasive pulmonary aspergillosis: clinical implications for antifungal therapy.

  2011cites this paper
• [Antifungal therapy update: new drugs and medical uses].

  2011cites this paper
• Characterization of the zinc cluster transcription factor Rds2 in «Saccharomyces cerevisiae» links glucose metabolism to antifungal drug resistance

  2011cites this paper
• Addressing current medical needs in invasive fungal infection prevention and treatment with new antifungal agents, strategies and formulations

  2011cites this paper
• Peroral Amphotericin B Polymer Nanoparticles Lead to Comparable or Superior In Vivo Antifungal Activity to That of Intravenous Ambisome® or Fungizone™

  2011cites this paper
• Azole Resistance in Aspergillus fumigatus—Current Epidemiology and Future Perspectives

  2011cites this paper
• Regulatory Circuitry Governing Fungal Development, Drug Resistance, and Disease

  2011cites this paper
• Newer antifungal agents

  2011cites this paper
• Colonização oral experimental por Candida albicans em camundongos imunossuprimidos e tratados com Lactobacillus acidophilus e Lactobacillus rhamnosus

  2011cites this paper
• Newer antifungal agents.

  2011cites this paper
• New lead structures in antifungal drug discovery.

  2011cites this paper
• Bibliography. Antimicrobial agents. Current world literature.

  2010cites this paper
• New antifungal agents for the treatment of candidaemia.

  2010cites this paper
• An insight into the antifungal pipeline: selected new molecules and beyond

  2010cites this paper